logo
logo

Evommune Closes $50 Million Series B Financing To Advance Broad Pipeline Of Therapies To Treat Chronic Inflammatory Diseases

Evommune Closes $50 Million Series B Financing To Advance Broad Pipeline Of Therapies To Treat Chronic Inflammatory Diseases

04/26/23, 11:33 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgpalo alto
Money raised
$50 million
Industry
biotechnology
health care
Round Type
series b
Investors
Andera Partners, Pivotal Bio Venture Partners, Amplitude Ventures, Sym Biosis, Eqt Life Sciences, Arix Bioscience
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing. The financing was co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, with participation from new and existing investors including Amplitude Ventures, and Series A leads Pivotal bioVenture Partners and Andera Partners.

Company Info

Company
Evommune
Location
palo alto, california, united states
Additional Info
Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is creating game-changing science with the goal of delivering therapies that address symptoms and halt progressive disease.

Related People